Company intelligence / Profile preview

Eno Research and Development

Hillsborough, North Carolina, USA

Ownership: Private
Development stage: Other

Overview

Eno Research and Development is a clinical-stage biotechnology company based in Hillsborough, North Carolina, specializing in the development of innovative cardiovascular imaging agents. The company's primary focus is on radiopharmaceuticals designed to improve the detection and management of coronary artery disease and myocardial ischemia. Its lead candidate, ENO-101, is a novel PET imaging agent that targets mitochondrial complex I to provide high-resolution assessments of myocardial perfusion. By leveraging advanced molecular imaging technologies, Eno Research and Development aims to provide clinicians with more accurate diagnostic tools for cardiovascular health.

Therapeutic areas: Cardiovascular
Modalities: RadiopharmaceuticalSmall molecule
Industry: Medical Imaging

Beyond the preview

Go deeper on Eno Research and Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eno Research and Development.

Explore the full profile